Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Jazz Pharmaceuticals Fourth Quarter Profit Surges on Sales of Xyrem

By Pharmaceutical Processing | March 8, 2011

PALO ALTO,
Calif. (AP) — Jazz Pharmaceuticals
Inc. said Monday that its fourth-quarter profit surged on a boost in sales of
its narcolepsy drug Xyrem.

The company earned $24.5 million, or 56 cents per share, up
from $5.7 million, or 17 cents per share, during the same period a year prior.
Revenue rose 40 percent to $53.4 million from $38.3 million.

Excluding charges, the company earned 63 cents per share.
Analysts surveyed by FactSet expected profit of 50 cents per share on $51.1
million in revenue.

Jazz markets Xyrem for daytime sleepiness in patients who
have narcolepsy, and also for cataplexy, a condition associated with narcolepsy
that causes sudden and brief losses of muscle control. Its other approved drug,
Luvox CR, is a treatment for obsessive compulsive disorder and social anxiety
disorder. The company said Xyrem revenue grew 36 percent to $42.9 million while
Luvox sales rose to 65 percent to $9.4 million. Jazz also reported about $1
million in revenue from royalties and contracts.

For the full year, the company earned $32.8 million, or 83
cents per share, compared with a loss of $6.8 million, or 23 cents per share,
in 2009. Revenue rose to $173.8 million from $128.4 million.

Looking ahead, the company expects adjusted profit in 2011
between $2.70 and $2.90 per share. Analysts expect $2.50 per share in profit.

Jazz shares jumped $1.01, or 3.7 percent, to $28.31 in
afterhours trading after rising 19 cents to close at $27.30 during the regular
trading session.

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards